Supernus Pharmaceuticals

MD - RockvillePharmaceutical1 H-1B visas (FY2023)

Focus: Supernus Pharmaceuticals is a specialty pharmaceutical company focused on small-molecule treatments in neurology, headquartered in Rockville, Maryland. The company generates revenue primarily from established branded neurological medications with significant Part D spending.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

5 recent layoff filings (12 mo) — 320 affected

2/27/2026 — 117 Waterworks Way Irvine CA 92618, CA · 58 affected · Layoff
2/27/2026 — 1555 Laguna Canyon Road Irvine CA 92618, CA · 176 affected · Layoff
2/27/2026 — 117 Waterworks Way Irvine CA 92618, CA · 58 affected · Layoff
+2 more

Source: state DOL filings via Big Local News

About Supernus Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Supernus Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

2 imminent

OXTELLAR XR

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

GOCOVRI

Schizophrenia, schizoaffective disorder

$92M

Peak12.3yr

Flagship product generating 55% of company revenue with extended patent protection through 2038.

Help build intelligence for Supernus Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

XADAGO

Idiopathic Parkinson Disease

N/A

Clinical Trials (1)

NCT03944785Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

N/A

National Pregnancy Registry for Psychiatric Medications

Pregnant Women

N/A

Assessment of Suicidality in Epilepsy - Rating Tools

Epilepsy

N/A

Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors

Impulsive Aggression

N/A

Clinical Trials (1)

NCT03615703Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors

N/A

Observational study

Parkinson Disease

N/A

Clinical Trials (1)

NCT07219927Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

N/A

ZULRESSO

Postpartum Depression

N/A

Clinical Trials (1)

NCT03924492Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression

N/A

SAGE-547

Super-Refractory Status Epilepticus

N/A

Clinical Trials (1)

NCT02433314An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus

N/A

Oxcarbazepine Extended Release

Epilepsy

N/A

Clinical Trials (1)

NCT00918424Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects

N/A

BIS-001 ER

Epilepsy, Complex Partial

Phase 1

Clinical Trials (1)

NCT03156439Bioavailability, Safety, and Tolerability of BIS-001 ER

Phase 1

SAGE-718

Huntington Disease

Phase 1

Clinical Trials (1)

NCT03787758A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Phase 1

SAGE-718

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03771586A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Phase 1

SAGE-718

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03770780A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Phase 1

[14C]-NV-5138

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05152680Mass Balance Study of NV-5138 in Healthy Male Subjects.

Phase 1

[14C]-NV-5138

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05384977Mass Balance Study of NV-5138 in Healthy Male Subjects

Phase 1

SAGE-718

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03844906A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

Phase 1

Topiramate IR

Epilepsy

Phase 1

Clinical Trials (1)

NCT01114854A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)

Phase 1

SPN-817, Treatment B

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT05102552Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

Phase 1

SPN-804O

Epilepsies, Partial

Phase 1

Clinical Trials (1)

NCT00918047Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

Phase 1

SPN-810M

Impulsive Aggression Comorbid With ADHD

Phase 1

Clinical Trials (1)

NCT02023606Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M

Phase 1

SAGE-904

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT05049343Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

Phase 1

SAGE-547

Super-refractory Status Epilepticus

Phase 1/2

Clinical Trials (1)

NCT02052739Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Phase 1/2

BIS-001ER

Focal Impaired Awareness Seizures

Phase 1/2

Clinical Trials (1)

NCT03474770BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Phase 1/2

IR Viloxazine

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 1/2

Clinical Trials (1)

NCT01107496Evaluation of Immediate-Release Viloxazine in Adults With ADHD

Phase 1/2

TPM XR

Epilepsy

Phase 1/2

Clinical Trials (1)

NCT01284530Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Phase 1/2

SAGE-718

Alzheimer Disease

Phase 2

Clinical Trials (1)

NCT04602624A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Phase 2

NV-5138

Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT06235905Open-Label of SPN-820 in Adults With Major Depressive Disorder

Phase 2

SPN-817

Focal Onset Seizures

Phase 2

Clinical Trials (1)

NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures

Phase 2

IR-TPM

Migraine

Phase 2

Clinical Trials (1)

NCT03280342Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine

Phase 2

Placebo

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Clinical Trials (1)

NCT02633527Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Phase 2

Molindone

Impulsive Aggression Comorbid With ADHD in Children

Phase 2

Clinical Trials (1)

NCT01416064Open-Label, Extension Study to 810P202

Phase 2

Functional Magnetic Resonance Imaging

Attention Deficit Hyperactivity Disorder (ADHD)

Phase 2

Clinical Trials (1)

NCT03638466Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

Phase 2

SAGE-718

Huntington's Disease

Phase 2

Clinical Trials (1)

NCT05107128A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Phase 2

SPN-817

Epilepsy

Phase 2

Clinical Trials (1)

NCT05518578Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Phase 2

SAGE-718

Huntington Disease

Phase 2

Clinical Trials (1)

NCT0535882128-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Phase 2

SPN-817

Focal Onset Seizures

Phase 2

Clinical Trials (1)

NCT07141329SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

Phase 2

Brexanolone

Tinnitus

Phase 2

Clinical Trials (1)

NCT05645432An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus

Phase 2

Gocovri

Radiation Encephalopathy

Phase 2

Clinical Trials (1)

NCT07125222Use of Gocovri to Improve Disability Due to Radiation Encephalopathy

Phase 2

SAGE-718

Parkinson Disease

Phase 2

Clinical Trials (1)

NCT04476017A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Phase 2

SAGE-547

Postpartum Depression

Phase 2

Clinical Trials (1)

NCT02285504Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

Phase 2

NV-5138

Treatment Resistant Depression

Phase 2

Clinical Trials (1)

NCT05066672Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Phase 2

SAGE-547

Severe Postpartum Depression

Phase 2

Clinical Trials (1)

NCT02614547A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Phase 2

SAGE-718-matching placebo

Parkinson Disease

Phase 2

Clinical Trials (1)

NCT05318937A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Phase 2

SPN-810

Attention Deficit Disorder With Hyperactivity

Phase 2

Clinical Trials (1)

NCT00626236Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Phase 2

SAGE-718

Mild Cognitive Impairment

Phase 2

Clinical Trials (1)

NCT05619692A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Phase 2

SPN-810

Impulsive Aggression Comorbid With ADHD

Phase 2

Clinical Trials (1)

NCT01364662A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

SPN-821 2400 mg

Major Depressive Disorder (MDD)

Phase 2

Clinical Trials (1)

NCT07226661Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Phase 2

Phase 2; Low Dose MYOBLOC

Spasticity

Phase 2/3

Clinical Trials (1)

NCT04099667Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity